<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237818</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH108-REC1-147</org_study_id>
    <nct_id>NCT04237818</nct_id>
  </id_info>
  <brief_title>The Evaluation of Chenopodium Formosanum and Fagopyrum Esculentum Extract on Anti-aging Effect</brief_title>
  <official_title>The Evaluation of Chenopodium Formosanum and Fagopyrum Esculentum Extract on Anti-aging Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCI Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCI Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess Chenopodium Formosanum and Fagopyrum Esculentum Extract on skin anti-aging
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of skin moisture</measure>
    <time_frame>Change from Baseline skin moisture at 8 weeks</time_frame>
    <description>Corneometer® CM825 is utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin elasticity</measure>
    <time_frame>Change from Baseline skin elasticity at 8 weeks</time_frame>
    <description>Cutometer® dual MPA 580 is utilized to measure skin elasticity (parameter R2). Units: μm penetration depth into the probe opening, expressed as curves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin wrinkles</measure>
    <time_frame>Change from Baseline skin wrinkles at 8 weeks</time_frame>
    <description>3D Full-Face Skin Analyzer IRV is utilized to measure wrinkles. Units: arbitrary units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin collagen density</measure>
    <time_frame>Change from Baseline skin collagen density at 8 weeks</time_frame>
    <description>DermaLab® combo - 20 MHz High Freq. Ultrasound probe is utilized to scan and analyze skin collagen density. Units: Intensity score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin tone</measure>
    <time_frame>Change from Baseline skin tone at 8 weeks</time_frame>
    <description>3D Full-Face Skin Analyzer IRV was utilized to measure skin tone. Units: arbitrary units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin brightness</measure>
    <time_frame>Change from Baseline skin brightness at 8 weeks</time_frame>
    <description>3D Full-Face Skin Analyzer IRV is utilized to measure skin brightness. Units: arbitrary units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin melanin index</measure>
    <time_frame>Change from Baseline skin melanin index at 8 weeks</time_frame>
    <description>Mexameter® MX 18 is utilized to measure skin melanin index. Units: arbitrary Mexameter® units (0-999)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of skin L*a*b* value</measure>
    <time_frame>Change from Baseline skin L*a*b* value at 8 weeks</time_frame>
    <description>Color Spectrophotometer SCM-104/108 is utilized to measure skin L*a*b* value. Units: arbitrary units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of transepidermal water loss (TEWL)</measure>
    <time_frame>Change from Baseline TEWL at 8 weeks</time_frame>
    <description>Tewameter® TM 300 is utilized to measure transepidermal water loss. Units: g/hm²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of skin texture</measure>
    <time_frame>Change from Baseline skin texture at 8 weeks</time_frame>
    <description>3D Full-Face Skin Analyzer IRV is utilized to measure skin texture. Units: arbitrary units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of skin pores</measure>
    <time_frame>Change from Baseline skin pores at 8 weeks</time_frame>
    <description>3D Full-Face Skin Analyzer IRV is utilized to measure skin pores. Units: arbitrary units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of skin spots</measure>
    <time_frame>Change from Baseline skin spots at 8 weeks</time_frame>
    <description>3D Full-Face Skin Analyzer IRV is utilized to measure skin spots. Units: arbitrary units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of skin erythema level</measure>
    <time_frame>Change from Baseline skin erythema level at 8 weeks</time_frame>
    <description>Mexameter® MX 18 is utilized to measure skin erythema level. Units: arbitrary Mexameter® units (0-999)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-assessment questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Questionnaire is utilized to assess skin condition of the subjects. Units: score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Skin Condition</condition>
  <arm_group>
    <arm_group_label>Placebo drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chenopodium Formosanum and Fagopyrum Esculentum Extract drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo drink</intervention_name>
    <description>consume 2 bottle (30 mL) per day for 56 days</description>
    <arm_group_label>Placebo drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chenopodium Formosanum and Fagopyrum Esculentum Extract drink</intervention_name>
    <description>consume 2 bottle (30 mL) per day for 56 days</description>
    <arm_group_label>Chenopodium Formosanum and Fagopyrum Esculentum Extract drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged between 20-65 years old

          -  Subjects must read and sign the informed consent form after the study has been fully
             explained.

          -  Subjects are willing to cooperate and comply with all of the regulation during the
             trial.

          -  Subject should inform to investigator immediately if adverse effect is happened.

          -  Subjects are willing to avoid UV overexposure during the trial (include indoor tanning
             treatment).

        Exclusion Criteria:

          -  Subjects who have known cosmetic, drug or food allergies.

          -  Subjects who have severe desquamation, tattoo, sunburn, peeling skin or other skin
             condition might impact measurement.

          -  Subjects with any physical condition judged by the researcher not to be eligible for
             this study.

          -  Subjects with uncontrollable physical condition such as high blood pressure, thyroid
             disease, diabetes, etc.

          -  Female who is pregnant or nursing or planning to become pregnant during the course of
             the study.

          -  Those who are currently participating in other clinical trials or who have just
             concluded a clinical trial two weeks ago.

          -  Women who have started contraceptive or change current hormone contraceptive methods
             within 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsiu-Mei Chiang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Po-Yuan Wu, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 19, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

